Literature DB >> 29249318

Defining resilience to mycobacterial disease: Characteristics of survivors of ovine paratuberculosis.

Kumudika de Silva1, Karren Plain2, Auriol Purdie2, Douglas Begg2, Richard Whittington3.   

Abstract

Paratuberculosis is an insidious, chronic disease of ruminants that has significant animal welfare implications and reduces on-farm profitability globally. Not all animals exposed to the causative pathogen, Mycobacterium avium subspecies paratuberculosis (MAP), succumb to disease and this unique, long-term trial was designed to track animals that were resilient. The advantages of understanding immune protection include the management option to retain resilient individuals in a herd/flock and the potential for deliberate manipulation of the host immune response using novel vaccines. Twenty sheep experimentally exposed to MAP and 10 controls were monitored for 2.5 years during which the condition progressed, resembling natural disease development. Cellular and humoral immune parameters and faecal MAP shedding were examined regularly and disease outcomes were classified at necropsy, based on the presence of viable MAP and histopathological lesions in intestinal tissues, either at the termination of the trial or when animals were culled due to weight loss. There were distinct characteristics, such as an early strong IFNγ response, that differentiated resilient sheep from susceptible individuals prior to the onset of clinical disease. Faecal MAP shedding and serum antibody level, commonly used to diagnose disease, were more ambiguous. The former was transient in the majority of resilient animals and therefore should not be used for diagnosis of MAP infection in younger animals. Remarkably, the serum antibody level in some resilient animals was higher than the usual positive-negative cut-off for disease diagnosis at multiple samplings throughout the trial. Consequently the antibody response in resistance to paratuberculosis requires further investigation.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody; Immunology; Interferon gamma; Mycobacterial infection; Paratuberculosis; Resilience; Sheep

Mesh:

Substances:

Year:  2017        PMID: 29249318     DOI: 10.1016/j.vetimm.2017.11.008

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  6 in total

Review 1.  Biomarkers for Detecting Resilience against Mycobacterial Disease in Animals.

Authors:  Kathryn Wright; Karren Plain; Auriol Purdie; Bernadette M Saunders; Kumudika de Silva
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

2.  Characterization of paucibacillary ileal lesions in sheep with subclinical active infection by Mycobacterium avium subsp. paratuberculosis.

Authors:  Salvatore Pisanu; Tiziana Cubeddu; Carla Cacciotto; Ylenia Pilicchi; Daniela Pagnozzi; Sergio Uzzau; Stefano Rocca; Maria Filippa Addis
Journal:  Vet Res       Date:  2018-12-04       Impact factor: 3.683

3.  Gene expression profiles during subclinical Mycobacterium avium subspecies paratuberculosis infection in sheep can predict disease outcome.

Authors:  Auriol C Purdie; Karren M Plain; Douglas J Begg; Kumudika de Silva; Richard J Whittington
Journal:  Sci Rep       Date:  2019-06-03       Impact factor: 4.379

Review 4.  Application of Transcriptomics to Enhance Early Diagnostics of Mycobacterial Infections, with an Emphasis on Mycobacterium avium ssp. paratuberculosis.

Authors:  Marielle H van den Esker; Ad P Koets
Journal:  Vet Sci       Date:  2019-06-26

5.  Flock sensitivity and specificity of pooled fecal qPCR and pooled serum ELISA for screening ovine paratuberculosis.

Authors:  Yoann Mathevon; Gilles Foucras; Fabien Corbière
Journal:  PLoS One       Date:  2019-12-26       Impact factor: 3.240

6.  Resilience to infection by Mycobacterium avium subspecies paratuberculosis following direct intestinal inoculation in calves.

Authors:  Kevin J Stinson; Monica M Baquero; Brandon L Plattner
Journal:  Vet Res       Date:  2018-07-13       Impact factor: 3.683

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.